EditorialPublished 31 Jan 2023
Hypoxanthine of Ischemic Brain Edema Modified by Glibenclamide
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The development of malignant brain edema is a leading cause of early clinical deterioration and death after ischemic stroke. Lesional swelling exacerbates tissue injury and portends poor long-term functional outcome after stroke. Malignant brain edema [1], the rapid clinical decline in the first 24–72 h after stroke due to mass-occupying tissue swelling, is a highly morbid sequela of large hemispheric stroke. Limited therapies exist for the treatment of brain edema.
Keywords
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Experimental Stroke & Translational Medicine
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Sun Jing”